Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: The potential impact of GABA concentration in the visual cortex

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 47, Issue , 2013, Pages 13-19

  Kelemen, Oguz ^a   Kiss, Imre ^b   Benedek, György ^c   Kéri, Szabolcs ^b,c,d  

^a BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Antipsychotics; Cognition; Contrast sensitivity; Motion perception; Schizophrenia; Vision

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; BIPERIDEN; CLONAZEPAM; CREATINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTRAST SENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAGNOCELLULAR RETINOGENICULOCORTICAL PATHWAY; MALE; MOTION COHERENCE TASK; MOVEMENT PERCEPTION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVE TRACT; OCCIPITAL CORTEX; PERCEPTION; PERCEPTION DISORDER; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; STEADY PEDESTAL TEST; STRUCTURED INTERVIEW FOR ASSESSING PERCEPTUAL ANOMALIES; VISUAL CONTRAST SENSITIVITY; VISUAL CORTEX;

ANALYSIS OF VARIANCE; ANOVA; ANTIPSYCHOTICS; C/D; COGNITION; CONTRAST SENSITIVITY; CR; CREATINE; CYCLES/DEGREE; GABA; GAMMA-AMINOBUTYRIC ACID; HONESTLY SIGNIFICANT DIFFERENCE; HSD; M; MAGNOCELLULAR; MOTION PERCEPTION; P; PANSS; PARVOCELLULAR; POSITIVE AND NEGATIVE SYNDROME SCALE; RBANS; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SIAPA; STRUCTURED INTERVIEW FOR ASSESSING PERCEPTUAL ANOMALIES; VISION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; CONTRAST SENSITIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MOTION PERCEPTION; NEUROPSYCHOLOGICAL TESTS; PERCEPTUAL DISORDERS; PHOTIC STIMULATION; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; VISUAL CORTEX; YOUNG ADULT;

EID: 84883310829     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.07.024     Document Type: Article

References (52)

1. Alexander K.R., Barnes C.S., Fishman G.A., Pokorny J., Smith V.C. Contrast sensitivity deficits in inferred magnocellular and parvocellular pathways in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2005, 45:4510-4519.
2. Antal A., Kéri Sz, Szekeres Gy, Szendi I., Kovács Z., Benedek Gy, et al. A szenzoros gátlási folyamatok zavara szkizofréniában I. A magnocelluláris pálya szelektív hiperaktivitása. Psychiatr Hung 1998, 13:679-684. [Article in Hungarian].
3. Benes F.M. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J Psychiatr Res 1997, 31:257-275.
4. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990, 13:296-302.
5. Bulens C., Meerwaldt J.D., van der Wildt G.J., Keemink C.J. Visual contrast sensitivity in drug-induced Parkinsonism. J Neurol Neurosurg Psychiatry 1989, 52:341-345.
6. Bunney W.E., Hetrick W.P., Bunney B.G., Patterson J.V., Jin Y., Potkin S.G., et al. Structured interview for assessing perceptual anomalies (SIAPA). Schizophr Bull 1999, 25:577-592.
7. Butler P.D., Silverstein S.M., Dakin S.C. Visual perception and its impairment in schizophrenia. Biol Psychiatry 2008, 64:40-47.
8. Chen Y. Abnormal visual motion processing in schizophrenia: a review of research progress. Schizophr Bull 2011, 37:709-715.
9. Chen Y., Levy D.L., Sheremata S., Nakayama K., Matthysse S., Holzman P.S. Effects of typical, atypical, and no antipsychotic drugs on visual contrast detection in schizophrenia. Am J Psychiatry 2003, 160:1795-1801.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV) 1996, American Psychiatric Press, Washington, DC.
11. Glass L. The Moire effect from random dots. Nature 1969, 223:578-580.
12. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry 1999, 156:1944-1950.
13. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull 2012, 38:950-957.
14. Goodbourn P.T., Bosten J.M., Hogg R.E., Bargary G., Lawrance-Owen A.J., Mollon J.D. Do different 'magnocellular tasks' probe the same neural substrate?. Proc Biol Sci 2012, 279:4263-4271.
15. Goto N., Yoshimura R., Kakeda S., Moriya J., Hori H., Hayashi K., et al. No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1480-1483.
16. Green M.F., Nuechterlein K.H., Mintz J. Backward masking in schizophrenia and mania. II. Specifying the visual channels. Arch Gen Psychiatry 1994, 51:945-951.
17. Harris J.P., Calvert J.E., Leendertz J.A., Phillipson O.T. The influence of dopamine on spatial vision. Eye 1990, 4:806-812.
18. Javitt D.C. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol 2009, 5:249-275.
19. Juhász L.Z., Kemény K., Linka E., Sántha J., Bartkó G. The use of RBANS test (repeatable battery for the assessment of neuropsychological status) in neurocognitive testing of patients suffering from schizophrenia and dementia. Ideggyogy Sz 2003, 56:303-308.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
21. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2012, 69:449-459.
22. Kéri S., Benedek G. Visual contrast sensitivity alterations in inferred magnocellular pathways and anomalous perceptual experiences in people at high-risk for psychosis. Vis Neurosci 2007, 24:183-189.
23. Kéri S., Benedek G. Why is vision impaired in fragile X premutation carriers? The role of fragile X mental retardation protein and potential FMR1 mRNA toxicity. Neuroscience 2012, 206:183-189.
24. Kéri Sz, Antal A., Szekeres Gy, Szendi I., Kovács Z., Benedek Gy, et al. A szenzoros gátlási folyamatok zavara szkizofréniában II. Kapcsolat a figyelemdeficittel. Psychiatr Hung 1999, 14:393-397. [Article in Hungarian].
25. Kéri S., Antal A., Szekeres G., Benedek G., Janka Z. Spatiotemporal visual processing in schizophrenia. J Neuropsychiatr Clin Neurosci 2002, 14:190-196.
26. Kéri S., Kiss I., Kelemen O., Benedek G., Janka Z. Anomalous visual experiences, negative symptoms, perceptual organization and the magnocellular pathway in schizophrenia: a shared construct?. Psychol Med 2005, 35:1445-1455.
27. Kéri S., Beniczky S., Kelemen O. Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia. Am J Psychiatry 2010, 167:444-450.
28. Kiss I., Fábián A., Benedek G., Kéri S. When doors of perception open: visual contrast sensitivity in never-medicated, first-episode schizophrenia. J Abnorm Psychol 2010, 119:586-593.
29. Klosterkötter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001, 58:158-164.
30. Leonova A., Pokorny J., Smith V.C. Spatial frequency processing in inferred PC- and MC-pathways. Vision Res 2003, 43:2133-2139.
31. Martín-Reyes M., Mendoza Quiñones R., Díaz de Villalvilla T., Valdés Sosa M. Perceptual/attentional anomalies in schizophrenia: a family study. Psychiatry Res 2010, 176:137-142.
32. McKendrick A.M., Badcock D.R., Gurgone M. Vernier acuity is normal in migraine, whereas global form and global motion perception are not. Invest Ophthalmol Vis Sci 2006, 47:3213-3219.
33. Mendoza Quiñones R., Martín Reyes M., Díaz de Villalvilla T., Bravo D.T., Caballero Moreno A., et al. Scale for assessing perceptual anomalies. Validation of a Spanish version of the SIAPA scale in a sample of Cuban schizophrenic patients. Actas Esp Psiquiatr 2007, 35:15-19.
34. Merigan W.H., Maunsell J.H. How parallel are the primate visual pathways?. Annu Rev Neurosci 1993, 16:369-402.
35. Mescher M., Merkle H., Kirsch J., Garwood M., Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998, 11:266-272.
36. Nassi J.J., Callaway E.M. Parallel processing strategies of the primate visual system. Nat Rev Neurosci 2009, 10:360-372.
37. Ongür D., Prescot A.P., McCarthy J., Cohen B.M., Renshaw P.F. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry 2010, 68:667-670.
38. Phillipson O.T., Harris J.P. Perceptual changes in schizophrenia: a questionnaire survey. Psychol Med 1985, 15:859-866.
39. Pokorny J. Review: steady and pulsed pedestals, the how and why of post-receptoral pathway separation. J Vis 2011, 11:1-23.
40. Pokorny J., Smith V.C. Psychophysical signatures associated with magnocellular and parvocellular pathway contrast gain. J Opt Soc Am A Opt Image Sci Vis 1997, 14:2477-2486.
41. Randolph C., Tierney M.C., Mohr E., Chase T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20:310-319.
42. Rokem A., Yoon J.H., Ooms R.E., Maddock R.J., Minzenberg M.J., Silver M.A. Broader visual orientation tuning in patients with schizophrenia. Front Hum Neurosci 2011, 5:127.
43. Skottun B.C., Skoyles J.R. Contrast sensitivity and magnocellular functioning in schizophrenia. Vision Res 2007, 47:2923-2933.
44. Skottun B.C., Skoyles J.R. On identifying magnocellular and parvocellular responses on the basis of contrast-response functions. Schizophr Bull 2011, 37:23-26.
45. Slaghuis W.L. Contrast sensitivity for stationary and drifting spatial frequency gratings in positive- and negative-symptom schizophrenia. J Abnorm Psychol 1998, 107:49-62.
46. Szamosi A., Kelemen O., Kéri S. Hippocampal volume and the AKT signaling system in first-episode schizophrenia. J Psychiatr Res 2012, 46:279-284.
47. Szulc A., Galinska-Skok B., Waszkiewicz N., Bibulowicz D., Konarzewska B., Tarasow E. Proton magnetic resonance spectroscopy changes after antipsychotic treatment. Curr Med Chem 2013, 20:414-427.
48. Tayoshi S., Nakataki M., Sumitani S., Taniguchi K., Shibuya-Tayoshi S., Numata S., et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2010, 117:83-91.
49. Treutwein B. Adaptive psychophysical procedures. Vision Res 1995, 35:2503-2522.
50. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
51. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89:211-224.
52. Yoon J.H., Maddock R.J., Rokem A., Silver M.A., Minzenberg M.J., Ragland J.D., et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 2010, 30:3777-3881.